HC Wainwright Raises Earnings Estimates for Pyxis Oncology

Key Points

• HC Wainwright raised Pyxis Oncology’s FY2030 EPS estimate to $0.79 from $0.76 and maintained a “Buy” rating with an $8.00 price target.
• Analyst sentiment is broadly positive: eight analysts rate the stock a Buy, one a Hold, and one a Sell, resulting in a consensus “Moderate Buy” rating and an $8.75 target price.
• Pyxis Oncology reported a quarterly loss of $0.40 per share, missing the $0.35 consensus estimate. The stock opened at $3.21, while institutional investors own approximately 39.1% of shares.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Equities researchers at HC Wainwright raised their FY2030 EPS estimates for shares of Pyxis Oncology in a research note issued to investors on Thursday, September 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.79 per share for the year, up from their previous forecast of $0.76. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.21) per share.

PYXS has been the subject of a number of other research reports. Wells Fargo & Company boosted their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an "overweight" rating in a research report on Wednesday, September 9th. Wedbush raised their target price on Pyxis Oncology from $6.00 to $8.00 and gave the stock an "outperform" rating in a report on Thursday. Weiss Ratings downgraded Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 30th. Finally, Leerink Partners cut their price target on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating for the company in a report on Thursday, July 2nd. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.75.

Pyxis Oncology Stock Performance

PYXS opened at $3.21 on Monday. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55. The company has a market capitalization of $267.75 million, a PE ratio of -2.28 and a beta of 1.34. The firm's 50 day simple moving average is $3.03 and its two-hundred day simple moving average is $2.24.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05).

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of PYXS. Bank of America Corp DE raised its position in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after purchasing an additional 9,062 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $81,000. XTX Topco Ltd bought a new position in Pyxis Oncology in the 2nd quarter worth $40,000. Marshall Wace LLP bought a new position in Pyxis Oncology in the 2nd quarter worth $163,000. Finally, Qube Research & Technologies Ltd increased its stake in Pyxis Oncology by 128.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock worth $113,000 after buying an additional 57,935 shares in the last quarter. 39.07% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.